The closely related non-receptor tyrosine kinases FEline Sarcoma (FES) and FEs Related (FER) are activated by cell surface receptors in hematopoietic cells. Despite the early description of oncogenic viral forms of fes, v-fes, and v-fps, the implication of FES and FER in human pathology is not known. We have recently shown that FES but not FER is necessary for oncogenic KIT receptor signaling. Here, we report that both FES and FER kinases are activated in primary acute myeloid leukemia (AML) blasts and in AML cell lines. FES and FER activation is dependent on FLT3 in cell lines harboring constitutively active FLT3 mutants. Moreover, both FES and FER proteins are critical for FLT3-internal tandem duplication (ITD) signaling and for cell proliferation in relevant AML cell lines. FER is required for cell cycle transitions, whereas FES seems necessary for cell survival. We concluded that FES and FER kinases mediate essential non-redundant functions downstream of FLT3-ITD.
Introduction
FLT3 is one of the most commonly mutated gene in acute myeloid leukemia (AML).
1,2 FLT3 is a transmembrane tyrosine kinase receptor strictly regulated under normal conditions by a combination of mechanisms that include structural autoinhibition, ligand binding, and receptor internalization. 3, 4 Oncogenic FLT3 are gain-of-function mutants with aberrantly regulated catalytic activity. These oncogenic mutations occur predominantly in the catalytic domain and in the regulatory cytoplasmic juxtamembrane region of the protein. 5 The most frequent mutation is the regulatory type mutation called internal tandem duplication (ITD), which occurs in about 25% of all AML. 1 The kinase domain mutations occur frequently, though not exclusively, at a conserved aspartic acid residue D835 located in the catalytic loop of the kinase domain. In addition, paracrine synthesis of FLT3 ligand may contribute to the proliferation of leukemic cells harboring wild-type FLT3. 6 Hence, therapeutic targeting of FLT3 has become a major challenge, leading to the development of selective tyrosine kinase inhibitors. 7 Oncogenic FLT3 receptors constitutively activate PI3-kinase, the MAP-kinases ERK1/2 and p38, LYN, and STAT5. 8 Although many studies have elucidated the mechanism of activation of these signaling pathways downstream of FLT3 mutants, little is known about their actual contribution to cellular transformation. The search for critical effectors of oncogenic FLT3 is of interest to identify alternative or complementary therapeutic targets in AML. FEline Sarcoma (FES) is a non-receptor tyrosine kinase homologous to the viral v-fes feline and v-fps avian oncogenes. 9 FES and FER (FES-related protein) constitute a distinct sub-family of non-receptor tyrosine kinases. 10 Below, we will refer to FES and FER collectively as FES kinases. Until very recently, neither c-fes nor fer gene product has been related to oncogenesis. However, a systematic search for mutations in kinase genes showed the presence of c-fes mutations in some colorectal cancers 11 and fer mutations in a small cell lung cancer 12 and in an endometroid carcinoma. 12 We have reported recently a function for FES downstream of the activated D816V KIT receptor, the most frequent oncogenic KIT mutant. 13 KIT mutations occur in about 5% of AML cases 14 and are implicated in the majority of gastro-intestinal stromal tumors 15 and mastocytosis. 16 In erythroleukemia and mastocytoma cell lines that harbor activating KIT mutations, FES has an essential role in KIT-dependent cell proliferation. 13 KIT and FLT3 are closely related receptors. Both are mutated in pathologies and both share similar gain-of-function mutations, arising from mutations in the catalytic domain and in the juxtamembrane regulatory region. We have therefore investigated whether FES kinases are implicated downstream of activated FLT3 receptor. Here, we provide evidence for essential functions of both FES and FER kinases downstream of FLT3-ITD in relevant AML cell lines. Downregulation of either kinase resulted in reduced proliferation of two FLT3-ITD-positive cell lines. However, FES and FER have distinct cellular functions as they differentially affect the cell cycle. Furthermore, signaling downstream of FLT3-ITD was severely impaired in cells with reduced level of either FES or FER, indicating that these cytoplasmic kinases are key effectors of oncogenic FLT3 receptor signaling.
Materials and methods

Cell lines
MV4-11 and MOLM-14 (kindly provided by Cell Biology Institute, Okayama, Japan) are human AML cell lines expressing FLT3-ITD mutations. 17 THP-1 is a human acute monocytic leukemia cell line expressing wild-type FLT3. TF-1 is a human erythroleukemia cell line that does not express FLT3. All cell lines were maintained in RPMI 1640 medium, supplemented with 10% fetal bovine serum and 2 mM L-glutamine (Invitrogen,
Small interfering RNA transfection
Small interfering RNAs (siRNA) and their sources were as follow. The human fes A-siRNA and fes B-siRNA, the human fer 1-siRNA, and the control-siRNA were described earlier. 13 The human fer 2-siRNA targeted the human fer sequence 5 0 -GGAG UGACCUGAAGAAUUCUU-3 0 (Dharmacon Research, Lafayette, CO, USA). The human flt3-siRNA was a mix of the following four duplexes 5 0 -CAAGAAACGACACCGGAUAUU-3 0 , 5 0 -GAAUUUAAGUCGUGUGUUCUU-3 0 , 5 0 -GCAAUGAUAU UUGGGACUAUU-3 0 , and 5 0 -CGCAACAGCUUAUGGAAUU UU-3 0 (SMARTpool siRNA, Dharmacon Research). siRNAs (0.4-0.8 nmol) were mixed with 10 7 cells in 0.2-0.5 ml of RPMI 1640 medium in 4 mm gap electroporation cuvettes. Electroporations were carried out at room temperature using a Gene Pulser Xcell System (Bio-Rad Laboratories, Munich, Germany) at 300 V and 950 mF for MV4-11 cells, 300 V and 800 mF for THP-1 cells (adapted from 18 ), 250 V and 20 ms for MOLM-14 cells, 19 and 250 V, 400 mF for TF-1 cells.
Antibodies
Anti-AKT, anti-p38 MAP-kinase, anti-PDK1, anti-phospho-PDK1 (Ser241), anti-phospho-GSK-3b (Ser9), anti-phospho-4E-BP1 (Thr37/46), anti-phospho-p70 S6-kinase (Thr389 and Thr421/ Ser424), anti-phospho-S6 ribosomal protein (Ser235/236), antiphospho-STAT5 (Tyr694), anti-phospho-SRC family (Tyr416) rabbit polyclonal antibodies and anti-BCL-xL rabbit monoclonal antibody were from Cell Signaling Technology (Beverly, MA, USA). Anti-FLT3, anti-ERK2, anti-GRB2, and anti-STAT5 rabbit polyclonal antibodies were from Santa Cruz Biotechnology (Heidelberg, Germany). Anti-active pan-ERK (Thr202/Tyr204) and anti-active p38 (Thr180/Tyr182) rabbit polyclonal antibodies were from Promega (Madison, WI, USA). The other antibodies used were anti-phosphotyrosine 4G10 (Upstate Biotechnology, Lake Placid, NY, USA), anti-LYN mouse monoclonal antibody (BD Biosciences, San Jose, CA, USA), anti-FES F113 rat monoclonal antibody (Calbiochem, Darmstadt, Germany), anti-FER rabbit polyclonal antibody (Millipore, Belford, MA, USA), anti-FER rabbit monoclonal antibody (Novus Biologicals, Littleton, CO, USA), and mouse IgG2b (Transduction Laboratories, Lexington, KY, USA). Anti-FES and anti-FER rat monoclonal antibodies were generated in our laboratory and used for immunoprecipitation experiments.
Immunoprecipitation and western blotting
Immunoprecipitation and western blots were performed as described earlier.
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Cell proliferation, cell cycle, and viability assays
In all, 5 Â 10 3 cells/well for MV4-11 and MOLM-14 cells and 10 4 cells/well for THP-1 and TF-1 cells were seeded into 96-well plates in 100 ml of RPMI 1640 medium with 10% fetal bovine serum and 2 mM L-glutamine. TF-1 cells were seeded with or without 250 ng/ml of human stem cell factor (Abcys). Cell proliferation assays by [methyl 3 H]-thymidine incorporation were carried out in sixplicates as described earlier. 13 Viable cell counts were carried out using the CellTiter-Glo luminescent cell viability assay using the manufacturer's instructions (Promega).
Carboxyfluorescein succinimidyl ester labelings were performed as described earlier. 13 A total of 4 Â 10 4 events were collected on an FACScan (Becton Dickinson, San Jose, CA, USA) and fluorescence intensity distribution was analyzed using Flow Jo software.
For BrdU and 7-amino-actinomycin D labeling, 10 6 cells were pulsed for 60 min at 37 1C with 1 mM BrdU solution. Staining was performed according to the BrdU Flow kit instructions (Becton Dickinson). A total of 10 4 events was collected on an FACScan and analyzed using Flow Jo software.
For senescence assay, 5 Â 10 3 cells were stained according to the Senescence b-galactosidase detection kit (Calbiochem). To determine the percentage of positive cells, three fields of 660 cells each were counted on cytospin preparations.
AML patient samples
Primary AML cells were obtained from blood or bone marrow of 10 patients on informed consent, using Ficoll-Hypaque densitygradient centrifugation. Blasts were immediately frozen in fetal calf serum supplemented with 10% dimethylsulfoxide. All patients were diagnosed according to the WHO classification at the Hematology Department of Institut Paoli-Calmettes (France). Leukemias were characterized in terms of morphology (French American British classification), karyotype, immunophenotype, and flt3 mutation status. The selected samples had normal karyotype and contained more than 75% leukemic blasts. This project has been reviewed and approved by the Internal Review Board of Institut Paoli-Calmettes.
Results
Activation of FES and FER in AML cell lines
On the basis of our previous finding that FES was phosphorylated downstream of KIT mutant D816V, an activated receptor tyrosine kinase related to FLT3, 13 we speculated that the FES family kinases FES and FER could be activated downstream of FLT3 gain-of-function mutants. To test this hypothesis, we evaluated the phosphorylation status of FES and FER in two AML cell lines with endogenous FLT3-ITD mutations, MV4-11 and MOLM-14. We and others have shown earlier that the activated forms of FES can be detected by immunoprecipitation using an anti-phosphotyrosine antibody. 13, 20, 21 Using this approach, we found that FES is phosphorylated in both cell lines ( Figure 1a) . FER is also present in the fraction of tyrosine phosphorylated proteins, suggesting that the activated form of FER can also be detected using this method ( Figure 1a ). These results were confirmed by probing immunoprecipitates, obtained using FERand FES-specific antibodies, with anti-phosphotyrosine antibody (Supplementary Figures S1A and S1B).
We then examined AML cell lines that do not have FLT3 mutations. THP-1 is an AML M5 cell line as MV4-11 and MOLM-14 cells used above, but expresses wild-type FLT3. TF1 is an AML M6-derived cell line that does not express FLT3. The activation status of FES kinases was determined in these two cell lines. Both 
FLT3-dependent activation of FES kinases
FES and FER are required for the proliferation of MV4-11 and MOLM-14 cells
To determine whether FES and FER are required for FLT3-ITD oncogenic signaling or are merely markers of FLT3-ITD activation, we individually knocked down FES and FER protein expression using RNA interference in the AML cell lines ( Figure 2 ). MV4-11 and MOLM-14 are strictly dependent on FLT3 for survival and proliferation. This was verified in our cells using siRNAs directed against FLT3 and thymidine incorporation assays or a viable cell count assay as a read-out (Figures 3a and b , flt3-siRNA). In these cell lines, reduced expression of either FES or FER dramatically reduced cell proliferation (Figures 3a and b) . In MV4-11, a 60% reduction of thymidine incorporation was observed relative to control cells. In MOLM-14, the reduction was similar to that obtained in flt3-siRNA-treated cells. Accordingly, the number of viable cells also decreased in cells with downregulated FES or FER, 2 days after the initial siRNA treatment (Figures 3a and b) . By contrast, reduction of FES or FER expression had no effect on cell proliferation in TF1 cells (Figure 3c ). In THP-1 cell line, in which FES kinases are activated (Figure 1a) , cell proliferation was only modestly reduced in the thymidine incorporation assay (Figure 3d ). We concluded that MV4-11 and MOLM-14 cellproliferations driven by the FLT3-ITD gain-of-function mutations require FES and FER.
Impaired cell cycle transitions in FER-deficient cells
The reduced cell proliferation defects could be attributed either to reduced cell survival and/or to cell cycle defects. To investigate the cell cycle, we labeled MV4-11 cells with carboxyfluorescein succinimidyl ester and estimated the number of cell divisions in the various siRNA-treated populations. Carboxyfluorescein succinimidyl ester is a fluorescent tag that binds cellular proteins covalently and is equally distributed among daughter cells after cell division. Cells transfected with fes-, fer-, or control-siRNA showed identical profiles immediately after staining (Supplementary Figure S4) . During the following days, the staining intensity was then used to evaluate the number of cell divisions in the three populations. The profile of Figure S4 . Cells with reduced FES expression and control cells showed similar labeling pattern with most cells having undergone five or six cell divisions. By contrast, the FER-deficient cells had higher fluorescent intensity and showed a broader peak. Indeed, the majority of FER-deficient cells in the population had only gone through three or four cell divisions, indicating that these cells have slower rate of cell division.
Activation of FES kinases in AML
Cell cycle analysis was then carried out on the three siRNAtreated cell populations using BrdU incorporation and DNA staining with 7-amino-actinomycin D. In this assay, FESdeficient cells and control cells displayed a similar distribution of cells in all three phases of the cell cycle (Supplementary Figure S5) . On the other hand, cells treated with fer-siRNA had fewer cells in S phase and showed accumulation of cells in G2. The number of cells in G1 was similarFalthough systematically more elevated in each experiment performedFto the control cells. The increased number of cells in G2 indicates an impaired G2/M transition. The fact that the number of cells in G1 is not decreased together with the depletion of cells in S phase suggests a dysfunctional G1/S phase transition too. Therefore, we concluded that FER but not FES is required for efficient cell cycle transitions in MV4-11. In conclusion, despite similar cell proliferation phenotype, FES and FER kinases Proliferation and cell viability were assessed 48 h later. Thymidine incorporation assays were used to evaluate cell proliferation (expressed as percentage of control), whereas an assay based on the quantification of ATP was used to estimate cell viability. Viability was not accessed in TF-1 because there was no effect on cell proliferation in this cell line. Fes A and fes B, and fer 1 and fer 2 are independent siRNA duplexes targeting fes and fer mRNAs, respectively. Histograms represent the results of three independent experiments.
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show distinct function on cell cycle downstream of FLT3 in MV4-11 cells.
Signs of senescence in FES-deficient cells
To investigate whether cell survival accounted for the cell proliferation defects, hallmarks of apoptosis, senescence or autophagy was looked for. We did not find evidence for signs of apoptosis, nor did we detect changes in LC3 expression, a marker of autophagosomes, in the siRNA-treated cells. However, senescence-associated b-galactosidase activity was increased in the population of fes-siRNA-treated cells compared to fer-and control-siRNA-treated cells (Supplementary Figure S6) . Therefore, FES-deficient cells seem to be prone to senescence. Together with the above resultsFthat is the cell proliferation deficiency and the lack of cell cycle defectsFthis suggests that FES is required for cell survival in MV4-11.
Altered FLT3-ITD signaling in the absence of FES or FER
To test whether FES kinases participate in FLT3-ITD signaling, we compared oncogenic FLT3 signaling in control MV4-11 cells and in MV4-11 cells depleted of either FES or FER. FLT3-ITD mutants activate the MAP-kinase pathways leading to ERK1/2 and p38 activation, the PI3-kinase pathway, SRC kinases, and STAT5 ( Figure 4 ). Cells treated either with fes-or fer-siRNA showed dramatic changes in key signaling events ( Figure 4 
FES and FER interact with FLT3
We identified earlier FES as a protein that interacts with KIT receptor. 13 As FES and FER have major impact on FLT3-ITD signaling, and as both proteins harbor an SH2 domain, we investigated the physical interaction between FLT3 and FES kinases. Endogenous FES proteins were immunoprecipitated from MV4-11 and MOLM-14 lysates using specific anti-FES or anti-FER monoclonal antibodies. FLT3 was indeed co-immunoprecipitated with FES and with FER, and not with the isotypecontrol antibody ( Figure 5 ). This experiment indicates that FES and FER are part of FLT3 receptor signaling complex. This may also explain the major impact of these proteins in FLT3-ITD downstream signaling.
FES kinases are phosphorylated in AML blasts
To evaluate whether FES kinases are expressed and phosphorylated in primary AML blasts, we screened 10 AML samples with high blast content either from blood (n ¼ 6) or bone marrow (n ¼ 4) (Supplementary Table S1 ). FES was activated in 5/10 samples whereas FER was phosphorylated in 3/10 samples (Figure 6a ). It is noteworthy that the level of expression of FES and FER was highlyvariable among these cells, and that the samples that did not show activation of the FES kinases are the ones with low or no detectable protein expression. Overall, 
FES kinases and wild-type FLT3 signaling
To determine whether FES kinases are involved in wild-type FLT3 signaling in AML cellular models, we have used RNA interference in the OCI-AML5 cell line. Stimulation of ERK1/2, AKT, and GSK3 pathways downstream of FLT3 was not affected by reduction of either FES or FER (Supplementary Figure S7) . In our experiments, cell survival of OCI-AML5 cells on serum withdrawal is dependent on FLT3-ligand, unlike cell proliferation. This anti-apoptotic effect of FLT3 stimulation was not impaired by reduction of FES or FER protein expression (Supplementary Figure S8) .
Discussion
In this study, we show that the two members of the FES family of kinases are essential mediators of oncogenic FLT3 signaling. The major results in support of this statement are that FES kinases are constitutively activated and that their targeted suppression in AML cell lines that express endogenous FLT3-ITD mutants impairs cell proliferation and have profound impact on signaling downstream of FLT3-ITD.
Many studies have deciphered signaling pathways activated downstream of FLT3. 8 However, it remains unclear whether the known mediators are essential for oncogenic FLT3 function. A key role for STAT5 is suspected, but to our knowledge there is no direct evidence to support this hypothesis. PIM-2, a serine/ threonine kinase encoded by STAT5 target genes, has been shown to participate in FLT3-ITD-mediated survival. 22 Using tyrosine kinase inhibitors and transfected murine IL-3-dependent cell lines, two studies have suggested that LYN is involved in the proliferation signal of FLT3-ITD. 23, 24 This was substantiated in one of the studies by RNA interference. 24 A recent study suggests that SHP2, an upstream activator of the ERK1/2 pathway, is dispensable for FLT3-ITD-dependent proliferation and transformation. 25 Furthermore, the PI3-kinase pathway seems to be dispensable for oncogenic FLT3. 26 The question of which effectors actually participate and are essential for functions such as cell proliferation and survival is critical to understand oncogenic FLT3 signaling. Essential effectors are of particular interest not only because they may be alternative targets in FLT3 mutant cells but also because they could participate in the evolution of the AML pathology independently of the FLT3 mutation statusFthat is they could be mutated in AML.
The findings reported here are important steps toward the identification of essential effectors of FLT3-ITD. Until now, FES kinases have not been linked to dysregulated receptor tyrosine kinase signaling. In MV4-11 cells, both FES and FER regulate the major pathways activated by mutant FLT3, suggesting that FES kinases control early events in FLT3 signaling. Alternatively, FES kinases may act as antagonists of negative feedback loops that normally occur under regulated signaling. Our study emphasizes the need to screen for new mediators of oncogenic kinases, beyond the classical signaling mediators.
A surprising finding of our study is that both FES and FER are individually required for FLT3 mutant signaling. Despite similar cell proliferation phenotype, they have different consequences on cell cycle in MV4-11 cells. Although FES deficiency did not affect the rate of cell division, FER deficiency resulted in slow cell cycling and accumulation of cells in G1 and G2 phases of the cycle. On the other hand, FES seems to be required for cell survival. The expression of the anti-apoptotic protein BCL-xL, which has been shown to contribute to survival downstream of FLT3-ITD, 26 was reduced in FES-deficient cells. Although we did not find that FES deficiency leads to apoptosis, the facts that FES-null cells divide at the same rate as the control cells and that the number of cells is lower in FES-treated compared with control cells strongly suggests that FES is required for cell survival. Interestingly, FES-deficient cells showed increased endogenous b-galactosidase activity, a hallmark of senescence. Therefore, cell survival is compromised when FES expression is reduced and our results suggest that FES counteracts oncogeneinduced senescence in MV4-11 cells.
FES and FER kinases were phosphorylated not only in AML cell lines but also in primary AML samples. In this small series of patients, the frequency of FES and/or FER activation is higher in the FLT3 mutant samples (four out of seven) than in the wildtype FLT3 samples (one out of three). Further analyses with increased number of samples will be needed to settle this question. In this series of AML blasts, FES kinases activation was not found in all samples with FLT3-ITD mutation. This has been reported also for other recognized FLT3-ITD downstream signaling effectors such as AKT 27 and STAT5. 28 This illustrates the complexity and variation within primary patient samples. 
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Conversely, FES and FER were phosphorylated in blasts and in an AML cell line that does not harbor FLT3 mutations, which suggests that other receptors or oncogenes can activate FES kinases in AML cells. Recently, we reported an essential function for FES downstream of KIT receptor mutant D816V. 13 Mutations at codon 816 in c-kit are the most frequent KIT mutations found in mastocytosis, AML, and germ cell tumors. In the context of KIT D816V receptor, FER was not implicated in cell proliferation. Furthermore, reminiscent of the function of FER in FLT3 signaling, FES was shown to facilitate the G1/S cell cycle transition. Therefore, FES kinases participate both in KIT and FLT3 oncogenic signaling but not in similar ways.
FES is dispensable for the proliferation mediated by wild-type KIT receptor, suggesting that KIT D816V mutant activates an illegitimate pathway for its oncogenic signaling. Whether it is also the case in the context of FLT3 is an important point. We have addressed this question using OCI-AML-5 cell line. In these cells, FES and FER were dispensable for WT FLT3 signaling. It remains to be elucidated whether it is also the case in context of normal physiology. Similarly, it is of interest to investigate whether the other classes of KIT and FLT3 mutants, KIT juxtamembrane or FLT3 D835 mutants, activate the FES kinases.
KIT and FLT3 are closely related receptors of the PDGFR subfamily of receptor tyrosine kinases. The activation of FES kinases in oncogenic signaling may be a hallmark of this subfamily of receptor. Alternatively, it could be a more general phenomenon implemented in many other transformed cells. Interestingly, Nir and colleagues have reported a role for FER in the proliferation of breast carcinoma and prostate cell lines. 29 In our study, we found that some AML cell lines and fresh AML blasts have activated FES and/or FER. Therefore, the activation status and the requirement for FES kinases should be investigated downstream of other oncogenic tyrosine kinases.
The unexpected function of FES and FER as essential effectors of oncogenic signaling raises the possibility that these two kinases could be mutated in leukemia and in other pathologies associated to flt3 and c-kit mutations. Screening for mutations in tyrosine kinase genes in a large cohort of de novo AML patients has been reported recently. 30, 31 One mutation was found in the kinase domain of FES but the analysis of this mutant was not conclusive. 30 In addition, four mutations in c-fes were reported in a similar screen in colon carcinoma. 11 The analysis of the respective mutant proteins revealed loss-of-function mutations rather than gain-of-function. 32, 33 It should be noted, however, that in these systematic searches for novel mutations, only the kinase encoding regions were sequenced and analyzed. Mutations in kinase genes also occur frequently in exons coding for regulatory regions of the protein (as in flt3). Sequencing of the entire coding sequence of kinases in human cancer cell lines and in human cancer revealed somatic mutations of c-fes in two cell lines 34 as well as mutations of fer in three cell lines 34 and two tumors. 12 These mutations have not been studied yet. There are no specific and selective inhibitors of either FES or FER reported to date. Only non-selective kinases inhibitors such as staurosporine have some impact on FES kinases catalytic activity. 35 The interest for FES kinases inhibitors was low until now because of the lack of evidence for the implication of FES kinases in human pathology. FES kinases are structurally different from other cytoplasmic tyrosine kinases. This may partially explain why inhibitors of other cytoplasmic protein tyrosine kinases fail to inhibit FES and FER. Selective inhibitors of FES and FER would be of great interest to address some of the fundamental questions raised above and to challenge the concept of FES kinases as therapeutic targets in AML.
In conclusion, our study suggests that FES and FER proteins, previously unrecognized in FLT3 signaling, are central mediators of oncogenic FLT3 signaling. The activation status and the precise function of these kinases should be considered in KIT and FLT3-related pathologies. These kinases could represent alternative therapeutic targets in leukemia.
